c‐erbB‐2 and c‐erbA‐1 (ear‐1) Gene Amplification and c‐erbB‐2 Protein Expression in Japanese Breast Cancers: Their Relationship to the Histology and Other Disease Parameters

Uehara, Tomoko; Kaneko, Yasuhiko; Kanda, Naotoshi; Yamamoto, Tadashi; Higashi, Youichirou; Nomoto, Chikao; Izumo, Toshiyuki; Takayama, Shojiro; Sakurai, Masaharu

doi:10.1111/j.1349-7006.1990.tb02618.x

Cited by 21 publications

(8 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Slamon et al [16], Pauley et al [23] and Yamada et al [24] have reported that c-erbB-2 amplification is proportional to the number of lymph node metastases. There was a correlation between the degree of c-erbB-2 amplification and the stage of disease [25] in our data, but other reports have seen no correlation [17,24,26].…”

Section: Discussioncontrasting

confidence: 53%

“…Although a statistical difference in the copy number of c-erbB-2 was not recognized in the groups with positive and negative distant metastases, or in the groups with positive and negative invasion to the pectoralis major muscle or skin, a tendency towards amplification of the c-erbB-2 gene was seen in patients with distant metastases and invasion to pectoralis major muscle or skin. Some reports have recognized a correlation between the degree of c-erbB-2 amplification and tumor size [26].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Quantitation of c-erbB-2 Gene Amplification in Breast Cancer Tissue by Competitive PCR

Okuyama¹,

Hatano²,

Park³

et al. 1999

Tumor Biol

View full text Add to dashboard Cite

Controversy exists regarding the relationship of the degree of c-erbB-2 amplification to other prognostic factors in breast cancer. To determine the degree of amplification of c-erbB-2 exactly, a sensitive and quantitative method is required. We have developed a competitive PCR method to quantitatively determine the amplification of the c-erbB-2 oncogene. Using this method, we evaluated DNA from 27 breast cancer tissue specimens and DNA from peripheral blood leukocytes from a normal individual. Regarding the relationship between the degree of c-erbB-2 amplification and clinicopathological factors, we found a greater degree of amplification of the c-erbB-2 oncogene in estrogen receptor- negative or progesterone receptor-negative specimens than in positive ones and in lymph node metastasis-positive specimens than in negative specimens, in stages II, III, and IV of disease compared with stage I disease, and in samples with positive lymphatic vessel invasion than with no lymphatic vessel invasion. Generally, these factors were seen in the group of patients who had a bad prognosis. By univariate analysis and multivariate analysis, reverse correlation was observed between amplification of c-erbB-2 and overall survival. Regarding disease-free survival, these relationships were observed only with univariate analysis in our group of patients.

show abstract

Section: Discussioncontrasting

confidence: 53%

Section: Discussionmentioning

confidence: 99%

Quantitation of c-erbB-2 Gene Amplification in Breast Cancer Tissue by Competitive PCR

Okuyama¹,

Hatano²,

Park³

et al. 1999

Tumor Biol

View full text Add to dashboard Cite

show abstract

“…In the study of Rossi et al, the percentage of cases with HER-2/ neu protein overexpression (3+) and FISH negativity rose to 22% (38). In the literature it is proposed that these 3+ cases could be due to single copy overexpression of the HER-2/neu gene (39). These cases are considered clinically similar to the immunohistochemically HER-2/neu negative patients (40 (42)(43)(44).…”

Section: Discussionmentioning

confidence: 99%

Correlation of her 2/neu gene amplification with immunohistochemistry and other prognostic factors in breast carcinoma

Ramadan¹,

Yapıcıer²,

Kihtir³

et al. 2011

TJPATH

View full text Add to dashboard Cite

The purpose of this study was to determine relationship between HER-2/neu status and estrogen receptor, progesterone receptor, grade and age by comparing fluorescence in situ hybridization and immunohistochemistry. One hundred invasive breast carcinomas were reviewed and fluorescence in situ hybridization analysis was performed in all cases. Immunohistochemical scores showed a perfect concordance with fluorescence in situ hybridization amplification ratios (p<0.0001). The results indicated a significant correlation between HER-2/neu and grade, but an inverse relationship between HER-2/neu and hormone receptors. In women aged ≤45 years, an inverse relationship between HER-2/neu and progesterone receptor was found and no association was noted between HER-2/neu and other factors. In women aged >45 years, the results indicated a significant correlation between HER-2/neu and grade, and there was an inverse relationship between HER-2/neu and hormone receptors.

show abstract

“…cerbB-2 expression has also been correlated with nuclear alterations in several studies of human breast cancer (14,(17)(18)(19), showing the existence of a correlation between a morphological and a biological factor.…”

Section: Introductionmentioning

confidence: 98%

c-erbB-2 expression and nuclear pleomorphism in canine mammary tumors

Dutra

Granja

Schmitt

et al. 2004

Braz J Med Biol Res

View full text Add to dashboard Cite

The objective of the present investigation was to study the expression of c-erbB-2 and MIB-1 and try to associate them with morphological features of the cell such as nuclear pleomorphism, mitotic count and histological grade in a series of 70 canine mammary gland tumors, 22 of them benign and 48 malignant. Tumors were collected at the Veterinary Hospital of UFMG (Brazil) and the Veterinary Faculty of Porto University (Portugal). c-erbB-2 expression was determined according to the guidelines provided by the manufacturer of the HercepTest system and nuclear pleomorphism, mitotic count and histological grade according the Elston and Ellis grading system. The HercepTest is the FDA-approved in vitro diagnostic test marketed by Dako. It is a semi-quantitative immunohistochemical assay used to determine overexpression of HER2 protein (human epidermal growth factor receptor) in breast cancer tissue. MIB-1 expression was also evaluated in 28 malignant tumors. Seventeen (35.4%) of the malignant tumors were positive for c-erbB-2 expression, which was positively associated with nuclear pleomorphism (P < 0.0001), histological grade (P = 0.0017) and mitotic count (P < 0.05). Nuclear pleomorphism also showed a positive association with MIB-1 index (P < 0.0001). These results suggest that some of the biological and morphological characteristics of the tumor are associated in canine mammary gland tumors, as also reported for human breast cancer. It was also possible to show that the immunoexpression of c-erbB-2 can be a factor in mammary carcinogenesis. This fact opens the possibility of using anti-c-erbB-2 antibodies in the treatment of canine mammary tumors.

show abstract

c‐erbB‐2 and c‐erbA‐1 (ear‐1) Gene Amplification and c‐erbB‐2 Protein Expression in Japanese Breast Cancers: Their Relationship to the Histology and Other Disease Parameters

Cited by 21 publications

References 9 publications

Quantitation of c-<i>erb</i>B-2 Gene Amplification in Breast Cancer Tissue by Competitive PCR

Quantitation of c-<i>erb</i>B-2 Gene Amplification in Breast Cancer Tissue by Competitive PCR

Correlation of her 2/neu gene amplification with immunohistochemistry and other prognostic factors in breast carcinoma

c-erbB-2 expression and nuclear pleomorphism in canine mammary tumors

Contact Info

Product

Resources

About